AJP - Heart Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 288: H1290-H1295, 2005. First published November 4, 2004; doi:10.1152/ajpheart.00796.2004
0363-6135/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/3/H1290    most recent
00796.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (45)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, G.
Right arrow Articles by Ping, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, G.
Right arrow Articles by Ping, P.

Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition

Guangwu Wang,1,2,* David A. Liem,1,2,* Thomas M. Vondriska,1,2 Henry M. Honda,2 Paavo Korge,2 Dawn M. Pantaleon,1,2 Xin Qiao,1 Yibin Wang,1,3 James N. Weiss,1,2 and Peipei Ping1,2

Departments of 1Physiology and Medicine, Divisions of 2Cardiology and 3Anesthesiology, David Geffen School of Medicine, University of California, Los Angeles, California

Submitted 5 August 2004 ; accepted in final form 23 October 2004

Mitochondrial permeability transition (MPT) pores have recently been implicated as a potential mediator of myocardial ischemic injury. Nitric oxide (NO) donors induce a powerful late phase of cardioprotection against ischemia-reperfusion injury; however, the cellular mechanisms involved are poorly understood. The role of MPT pores as a target of cardioprotective signaling pathways activated by NO has never been explored in detail. Thus mice were administered the NO donor diethylenetriamine (DETA)/NO (4 doses of 0.1 mg/kg iv each) 24 h before 30 min of coronary artery occlusion followed by 24 h of reperfusion. Infarct size was significantly reduced in DETA/NO-treated mice (30 ± 2% of risk region in treated mice vs. 50 ± 2% in control mice; P < 0.05), which demonstrates powerful cardioprotection. To examine the role of MPT pores, mice were administered atractyloside (Atr; 25 mg/kg iv), which induces adenine nucleotide translocase-dependent MPT, 20 min before ischemia. Atr blocked the infarct-sparing effects of DETA/NO (infarct size, 58 ± 1 vs. 30 ± 2% of risk region in DETA/NO; P < 0.05), whereas Atr alone had no effect. Mitochondria isolated from DETA/NO-treated mice exhibited increased resistance to Ca2+-induced swelling by 20 µmol/l CaCl2 or by the higher concentration of 200 µmol/l, which suggests that cardioprotection involves decreased propensity for MPT. Preincubation of mitochondria from control hearts with 30 nmol/l of the pore inhibitor cyclosporin A prevented swelling by 200 µmol/l CaCl2, thereby confirming that Ca2+ induces mitochondrial swelling via MPT. In accordance with the effects on infarct size, administration of Atr to the mice significantly abrogated DETA/NO-induced protection against Ca2+-induced mitochondrial swelling. These phenotypic alterations were associated with an increase in the antiapoptotic protein Bcl-2, which suggests that the underlying mechanisms may involve inhibition of cell death by Bcl-2. These data suggest that a critical process during NO donor-induced cardioprotection is to prevent MPT pore opening potentially via targeting of the adenine nucleotide translocator.

myocardial infarct size; apoptosis; preconditioning; adenine nucleotide translocase; atractyloside



Address for reprint requests and other correspondence: P. Ping, Cardiovascular Research Laboratories, Depts. of Physiology and Medicine, Division of Cardiology, David Geffen School of Medicine at UCLA, Rm. 1619 MRL Bldg., Los Angeles, CA 90095 (E-mail: peipeiping{at}earthlink.net)




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
S. Javadov, M. Karmazyn, and N. Escobales
Mitochondrial Permeability Transition Pore Opening as a Promising Therapeutic Target in Cardiac Diseases
J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 670 - 678.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. M. Nadtochiy, P. R.S. Baker, B. A. Freeman, and P. S. Brookes
Mitochondrial nitroalkene formation and mild uncoupling in ischaemic preconditioning: implications for cardioprotection
Cardiovasc Res, May 1, 2009; 82(2): 333 - 340.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
E. N. Dedkova and L. A. Blatter
Characteristics and function of cardiac mitochondrial nitric oxide synthase
J. Physiol., February 15, 2009; 587(4): 851 - 872.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. Ananthakrishnan, M. Kaneko, Y. C. Hwang, N. Quadri, T. Gomez, Q. Li, C. Caspersen, and R. Ramasamy
Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondrial permeability transition pore
Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H333 - H341.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
L. Wang, N. Oka, M. Tropak, J. Callahan, J. Lee, G. Wilson, A. Redington, and C. A. Caldarone
Remote ischemic preconditioning elaborates a transferable blood-borne effector that protects mitochondrial structure and function and preserves myocardial performance after neonatal cardioplegic arrest.
J. Thorac. Cardiovasc. Surg., August 1, 2008; 136(2): 335 - 342.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. E. McAllister, H. Ashrafpour, N. Cahoon, N. Huang, M. A. Moses, P. C. Neligan, C. R. Forrest, J. E. Lipa, and C. Y. Pang
Postconditioning for salvage of ischemic skeletal muscle from reperfusion injury: efficacy and mechanism
Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2008; 295(2): R681 - R689.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. D. T. Costa and K. D. Garlid
Intramitochondrial signaling: interactions among mitoKATP, PKC{varepsilon}, ROS, and MPT
Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H874 - H882.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
N. Oka, L. Wang, W. Mi, W. Zhu, O. Honjo, and C. A. Caldarone
Cyclosporine A prevents apoptosis-related mitochondrial dysfunction after neonatal cardioplegic arrest
J. Thorac. Cardiovasc. Surg., January 1, 2008; 135(1): 123 - 130.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
D. A. Liem, H. M. Honda, J. Zhang, D. Woo, and P. Ping
Past and present course of cardioprotection against ischemia- reperfusion injury
J Appl Physiol, December 1, 2007; 103(6): 2129 - 2136.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
P. A. Townsend, S. M. Davidson, S. J. Clarke, I. Khaliulin, C. J. Carroll, T. M. Scarabelli, R. A. Knight, A. Stephanou, D. S. Latchman, and A. P. Halestrap
Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress
Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H928 - H938.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
A. Robinet, H. Millart, F. Oszust, W. Hornebeck, and G. Bellon
Binding of elastin peptides to S-Gal protects the heart against ischemia/reperfusion injury by triggering the RISK pathway
FASEB J, July 1, 2007; 21(9): 1968 - 1978.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
G. Kroemer, L. Galluzzi, and C. Brenner
Mitochondrial Membrane Permeabilization in Cell Death
Physiol Rev, January 1, 2007; 87(1): 99 - 163.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
M. B. West, B. G. Hill, Y.-T. Xuan, and A. Bhatnagar
Protein glutathiolation by nitric oxide: an intracellular mechanism regulating redox protein modification
FASEB J, August 1, 2006; 20(10): 1715 - 1717.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. M. Davidson and M. R. Duchen
Effects of NO on mitochondrial function in cardiomyocytes: Pathophysiological relevance
Cardiovasc Res, July 1, 2006; 71(1): 10 - 21.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. Garcia-Dorado, A. Rodriguez-Sinovas, M. Ruiz-Meana, J. Inserte, L. Agullo, and A. Cabestrero
The end-effectors of preconditioning protection against myocardial cell death secondary to ischemia-reperfusion
Cardiovasc Res, May 1, 2006; 70(2): 274 - 285.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Guo, A. B. Stein, W.-J. Wu, X. Zhu, W. Tan, Q. Li, and R. Bolli
Late preconditioning induced by NO donors, adenosine A1 receptor agonists, and {delta}1-opioid receptor agonists is mediated by iNOS
Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2251 - H2257.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.